SLC5A2 and diabetic kidney disease: Considering the described close interplay between inflammation and metabolic deregulation and the beneficial effects of SGLT-2 inhibition observed in diseases with metabolic and inflammatory disorders (type 2 diabetes, heart failure, diabetic nephropathy, diabetic cardiomyopathy), it is natural to investigate its role as a therapeutic agent with anti-inflammatory effects [13].